



THE REPUBLIC OF CYPRUS

Department of Registrar of Companies and Official Receiver

**ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ
ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS**

**ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ CY1985
PUBLICATION NUMBER**

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2260763

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1^η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

**The document provided hereafter was filed at "The Patent Office"
in England under the law CAP.266 before the 1st of April 1998.
It was published afterwards by the UK patent office only in English.**

(21) Application No 9224764.2

(22) Date of filing 12.07.1991

(30) Priority data

(31) 9015473 (32) 13.07.1990 (33) GB

(86) International application data

PCT/GB91/01150 En 12.07.1991

(87) International publication data

WO92/00965 En 23.01.1992

(71) Applicant

The Wellcome Foundation Limited

(Incorporated in the United Kingdom)

PO Box 129, Unicorn House, 160 Euston Road,
London, NW1 2BP, United Kingdom

(72) Inventors

Derek Anthony Hill

Geoffrey Lloyd Turner

(74) Agent and/or Address for Service

A J Rollins

The Wellcome Foundation Limited,
Langley Court, South Eden Park Road, Beckenham,
Kent, BR3 3BS, United Kingdom

(51) INT CL⁵

C07D 217/20, A61K 31/485

(52) UK CL (Edition L)

C2C CAA CBE C1535 C213 C22Y C220 C25Y C250
C251 C28X C29Y C290 C30Y C302 C36Y C364
C366 C368 C638 C644 C65X C658 C662 C672
C699 C80Y C802
U1S S2416

(56) Documents cited by ISA

GB 1579822 A

European Journal of Medicinal Chemistry, Chimie
Therapeutique 19(5) pages 441-450

(58) Field of search by ISA

INT CL⁵ C07D 217/00

(54) Neuromuscular blocking agents

(57) 1R-*cis*,1'R-*cis* isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium) salt, substantially free from other geometrical and optical isomers thereof. The 1R-*cis*,1'R-*cis* isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockage, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockade), in comparison with the known mixture of geometrical and optical isomers.